Product details
Tesamorelin is a synthetic 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoyl modification that protects the molecule from DPP-4 cleavage and extends the plasma half-life relative to native GHRH or unmodified Sermorelin. It is the only FDA-approved member of the GHRH-analog class, indicated as a finished drug (Egrifta) for HIV-associated lipodystrophy and the reduction of excess visceral abdominal fat in HIV-positive patients with lipodystrophy.
Peptuno supplies Tesamorelin acetate as a lyophilized powder at ≥99.0% HPLC purity. The 44-residue sequence is at the upper-middle range for SPPS, and the analytical packet emphasizes peak-integration HPLC plus ESI mass spec confirming the N-terminal hexenoyl modification, the modified mass is the diagnostic identity check. Sequence verification by LC-MS/MS is available on request and is recommended at first-time supplier qualification because the hexenoyl group's positional integrity matters for biological activity. Tesamorelin is most commonly ordered as the standalone vial for visceral-fat research and compounding workflows, or as the pre-blended Tesamorelin + Ipamorelin combination (the tesa-ipa-blend SKU) for dual-pathway GH-axis research.
Regulatory note: The finished Tesamorelin drug (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Peptuno supplies the bulk active strictly for Research Use Only; buyers are responsible for verifying ingredient eligibility in their destination market.
FAQ
- How is Tesamorelin different from the other GHRH analogues?
- Tesamorelin is the only FDA-approved GHRH analogue as a finished drug, distinguishing it from Sermorelin (which had a now-discontinued approval), CJC-1295 (no approval), and Modified GRF 1-29 (no approval). Mechanistically, Tesamorelin's N-terminal trans-3-hexenoyl modification gives it both better protease resistance than unmodified Sermorelin and a half-life roughly similar to CJC-1295 no-DAC, but at lower mass-equivalent because the hexenoyl group is a small modification rather than the larger substitutions used in CJC-1295. Tesamorelin's specific clinical context, visceral-fat reduction in HIV-associated lipodystrophy, drove most of the rigorous PK and clinical-outcome data in this family.
- What's the recommended analytical packet for first-time Tesamorelin qualification?
- For first-time supplier qualification of Tesamorelin, request: (1) HPLC chromatogram with peak integration showing ≥99.0% main-peak area, (2) ESI mass spec confirming the modified mass (≈5135.8 Da for Tesamorelin vs. ≈3358 Da for unmodified Sermorelin 1-29, the mass difference is diagnostic of the hexenoyl modification, but it's also worth confirming the modified peak is the dominant species), (3) LC-MS/MS sequence verification covering the N-terminal residues to confirm the hexenoyl is positioned correctly, and (4) water content + counter-ion. For in vivo research workflows add LAL endotoxin and USP <61>/<62> microbial limits.
- Can Tesamorelin be combined with Ipamorelin like CJC-1295 is?
- Yes, the GHRH-receptor agonist plus GHSR agonist combination strategy applies equally to Tesamorelin. Peptuno supplies pre-blended co-lyophilised Tesamorelin + Ipamorelin vials under the tesa-ipa-blend SKU at standard 10+5 mg total ratios (custom ratios via Peptuno's custom-synthesis programme). The mechanistic rationale matches the CJC-1295 + Ipamorelin combination: two parallel input pathways converging on somatotroph GH release produce additive magnitudes beyond either component alone.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.
Related products
Sermorelin
GHRH 1-29 fragment
CJC-1295 (no DAC)
Modified GRF 1-29 · GHRH analog
Tesamorelin + Ipamorelin Blend (15 mg)
Co-characterized GH-axis pairing (Tesamorelin + Ipamorelin)